Profile from Yahoo: ACYT develops, manufactures and markets the only integrated automated sample preparation and image analysis system to support cytotechnologists and pathologists in cervical cancer screening. For the nine months ended 9/97, net sales rose 39% to $1.7 million. Net loss rose 12% to $8.8 million. Revenues reflect sales and marketing efforts being more directed to cytology products. Loss reflects higher clini-cal trial costs and $1.5 million commitment fee costs for warrants.
Comments:This stock looks like to take off when FDA give its product a final approval. Recently released company news suggest that the FDA approval is imminent. The company's product will probably distributed through Roche's affiliates. Roche indirectly hold a large % of acyt shares. The management team also hold a substantial amount of shares, some of which were aquired in the open market at ~$10 range. Technically, the stock looks like to go to is initial price of $13. It is very likely that $13 target will be hit in next 12 months. |
